| Автор | Scherließ, Regina |
| Автор | Buske, Simon |
| Дата выпуска | 2012 |
| ISBN | 978-1-84973-378-6 |
| dc.description | Intranasal administration of nanoparticulate dry powder vaccine formulations seems to be an advantageous option due to the fact that particles smaller than 250 nm can be taken up by specialized cells (M-cells) in the mucosa resulting in both local and systemic immune response. Among other reactions this causes the secretion of dimeric IgA (sIgA) into the mucus promoting entrapment of pathogens directly in the mucus1.In this study non-water soluble nanoparticles of chitosan and sodium deoxycholate were prepared via ionic coacervation. The particle size distribution of the products was determined via photon correlation spectroscopy (PCS). The obtained particles showed a monomodal distribution with an average size of about 250 nm (size distribution by volume). These particles seem to be ideal carriers for model antigens such as bovine serum albumin (BSA), which can be incorporated during the particle forming process. In order to obtain a dry powder the nanosuspension can be spray dried or freeze dried using mannitol as matrix. Spray-dried products are known for having a particle size of less than 10 µm. The product can be re-dispersed rapidly resulting in a nanoparticulate dispersion.. For nasal application, the spray dried formulation can be used directly as dry powder vaccine or may be further processed in order to obtain a suitable formulation by immobilisation onto bigger carrier particles to allow preferential nasal deposition. Such formulations might represent a promising vaccine delivery system in the near future. |
| Формат | application.pdf |
| Издатель | Royal Society of Chemistry |
| Название | Dry Powder Nanoparticulate Formulations for Mucosal Vaccination |
| Тип | other |
| DOI | 10.1039/9781849735247-00104 |
| Print ISSN | 0260-6291 |
| Журнал | NanoFormulation |
| Первая страница | 104 |
| Последняя страница | 112 |
